Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Bullboard Posts
Post by Straniuson Nov 14, 2017 2:23pm
163 Views
Post# 26961536

Long Revive at Current Levels - A No Brainer

Long Revive at Current Levels - A No BrainerIt's hard to understand how this name is trading with a market cap of $12M when the large growers are on a tear with valuations of several billions of dollars. 

If nothing else, at some point someone at one of these large Canadian growers will figure out a name like RVV is a cheap cheap way to acquire a cannabis bio-science company. Given their multi-billion dollar valuation, acquiring someone like an RVV, is a very inexpensive option on the bio-science space rather than developing it themselves and get a leg up on their producer competitors.

What we are seeing now is bumping up against resistance of a slew of disenfranchised shareholders that have become tired of holding this at a loss from pre-May 2017 (everyone that purchased above the pink line in chart below) and those tired of hoping for a run since May 2017 (everyone that purchased below the pink line in chart below).

Once we break through this initial resistance we should see a rerating in the valuation of this name

~S


User image
Bullboard Posts